U.S., Jan. 30 -- ClinicalTrials.gov registry received information related to the study (NCT06798415) titled 'Intralesional Injection of Metronidazole for the Management of Cutaneous Leishmaniasis' on Jan. 17.
Brief Summary: Aim of the study to evaluate the effectiveness of intralesional metronidazole 0.5% solution as a local injection in treating cutaneous leishmaniasis.
In an open-label single-arm clinical trial, all patients will be given intralesional levofloxacin injections; the patients had cutaneous leishmaniasis lesions. Each lesion will be considered a case in the final analysis. Each lesion will be followed up for 90 days (censor endpoint) or until the lesions are cured.
Intralesional metronidazole (5 mg/ml, 100 ml, Flagyl(R), S...